Pam Harrison


IV Calcium/Magnesium Has No Effect on Oxaliplatin-Induced Neuropathy

July 6th 2013

Intravenous calcium plus magnesium given before or after adjuvant FOLFOX chemotherapy has absolutely no effect on the development of sensory neurotoxicity induced by oxaliplatin.

Simple, Inexpensive Blood Test Poised to Be a Real "Game Changer" in CRC Screening

July 6th 2013

A simple and inexpensive blood test is being developed that can be used to screen patients for premalignant colorectal cancer lesions which, once perfected, will be a real game changer.

Better Responders in VELOUR Derive Enhanced Benefit From Aflibercept

July 6th 2013

Better responders within a cohort of patients from the VELOUR study derive enhanced benefit from aflibercept when combined with FOLFIRI, a post-hoc analysis of the study shows.

Novel VEGFR-2 Inhibitor Prolongs Survival in Advanced Gastric/GEJ Adenocarcinoma

July 5th 2013

Ramucirumab significantly prolongs survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma following progression on first-line therapy.

Nab-paclitaxel Plus Gemcitabine a Strong Predictor of Survival in Metastatic Pancreatic Cancer

July 4th 2013

Treatment with weekly nab-paclitaxel plus gemcitabine remains a strong independent predictor of both OS and PFS in patients with metastatic pancreatic cancer compared with gemcitabine alone.

Gemcitabine Response Depends on Gene Expression in Patients With Pancreatic Cancer

July 4th 2013

Patients who express low levels of a critical gene involved in transporting gemcitabine into pancreatic tumor cells have virtually no overall survival advantage from treatment with the drug in the adjuvant setting.